Perspectives for yttrium-90 radioembolization as therapeutic option for hepatocellular carcinoma

Marta Burrel,Patricia Bermúdez, Alejandro Forner González

REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS（2022）

引用 0|浏览5

暂无评分

摘要

The therapeutic management of hepatocellular carcinoma (HCC) has achieved great advances in the past few years. Before the publication of the SHARP clinical trial, which showed the effectiveness of sorafenib in patients with advanced HCC, no effective systemic therapy was available and only transarterial chemoembolization (TACE) had shown an impact on survival in clinical trials.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要